Stay updated with breaking news from 46433010. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday. A number of other brokerages also recently issued reports on IONS. Stifel Nicolaus increased their price objective on Ionis Pharmaceuticals from $45.00 to $50.00 and […]
BLB&B Advisors LLC decreased its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 1.8% in the third quarter, Holdings Channel reports. The firm owned 147,650 shares of the company’s stock after selling 2,650 shares during the quarter. BLB&B Advisors LLC’s holdings in Ionis Pharmaceuticals were worth $6,697,000 as of its most recent SEC […]
Simplicity Solutions LLC lowered its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 2.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,198 shares of the company’s stock after selling 267 shares during the period. Simplicity Solutions LLC’s holdings in Ionis […]
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) EVP Patrick R. O’neil sold 20,825 shares of the business’s stock in a transaction dated Tuesday, December 26th. The stock was sold at an average price of $51.46, for a total value of $1,071,654.50. Following the transaction, the executive vice president now owns 40,355 shares of the […]
DAVENPORT & Co LLC cut its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 1.1% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 86,877 shares of the company’s stock after selling 940 shares during the quarter. DAVENPORT & Co LLC’s holdings in Ionis Pharmaceuticals were worth $3,941,000 as of its most recent […]